Asset Details
Do you wish to reserve the book?
Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
Do you wish to request the book?
Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
2025
Overview
Background
There is a need to better reflect the patient experience in multiple myeloma (MM), beyond just clinical progression, with the use of a novel endpoint that combines disease progression with patient-reported outcomes.
Methods
A systematic literature review (SLR) identified relevant MM symptoms, which were narrowed down by experts using a Delphi panel. A post-hoc analysis of the MagnetisMM-3 trial of elranatamab assessed the impact of change in patient-reported outcomes (PROs) on the risk of disease progression or death. A composite endpoint for symptomatic progression-free survival (SPFS) combined these symptoms and PFS (PFS event plus 10-point worsening in pain, fatigue, or poor mobility within 28 days).
Results
The SLR identified 16 symptoms from 34 publications. Delphi consensus was that drowsiness, fatigue, pain, and poor mobility are linked to disease progression. Three symptoms had a significant association with PFS: A 10-point worsening on the 100-point scales for pain, fatigue, and poor mobility corresponded to a 22%, 20%, and 31% increase in risk of progression, respectively. Median SPFS was not reached (95% CI 12.2- not reached).
Conclusions
SPFS is the first composite endpoint in MM that combines PFS and clinically relevant PROs. The patient-centric approach in the conception of this endpoint allows for a nuanced and comprehensive understanding of the MM patient experience.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Europe
/ Fatigue
/ Health Promotion and Disease Prevention
/ Humans
/ Leukemia
/ Mobility
/ Multiple Myeloma - diagnosis
/ Multiple Myeloma - drug therapy
/ Multiple Myeloma - mortality
/ Oncology
/ Pain
/ Patient Reported Outcome Measures
/ Patients
/ Survival
